Internet of things-based approach for glycemic control in people with type 2 diabetes: A randomized controlled trial

IF 3.1 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Ryotaro Bouchi, Kazuo Izumi, Naoki Ishizuka, Yukari Uemura, Hiroshi Ohtsu, Kengo Miyo, Shigeho Tanaka, Noriko Satoh-Asahara, Kazuo Hara, Masato Odawara, Yoshiki Kusunoki, Hidenori Koyama, Takeshi Onoue, Hiroshi Arima, Kazuyo Tsushita, Hirotaka Watada, Takashi Kadowaki, Kohjiro Ueki
{"title":"Internet of things-based approach for glycemic control in people with type 2 diabetes: A randomized controlled trial","authors":"Ryotaro Bouchi,&nbsp;Kazuo Izumi,&nbsp;Naoki Ishizuka,&nbsp;Yukari Uemura,&nbsp;Hiroshi Ohtsu,&nbsp;Kengo Miyo,&nbsp;Shigeho Tanaka,&nbsp;Noriko Satoh-Asahara,&nbsp;Kazuo Hara,&nbsp;Masato Odawara,&nbsp;Yoshiki Kusunoki,&nbsp;Hidenori Koyama,&nbsp;Takeshi Onoue,&nbsp;Hiroshi Arima,&nbsp;Kazuyo Tsushita,&nbsp;Hirotaka Watada,&nbsp;Takashi Kadowaki,&nbsp;Kohjiro Ueki","doi":"10.1111/jdi.14227","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>The utilization of long-term effect of internet of things (IoT) on glycemic control is controversial. This trial aimed to examine the effect of an IoT-based approach for type 2 diabetes.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>This randomized controlled trial enrolled 1,159 adults aged 20–74 years with type 2 diabetes with a HbA1c of 6.0–8.9% (42–74 mmol/mol), who were using a smartphone on a daily basis were randomly assigned to either the IoT-based approach group (ITG) or the control group (CTG). The ITG were supervised to utilize an IoT automated system that demonstrates a summary of lifelogging data (weight, blood pressure, and physical activities) and provides feedback messages that promote behavioral changes in both diet and exercise. The primary end point was a HbA1c change over 52 weeks.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among the patients, 581 were assigned to the ITG and 578 were in the CTG. The changes in HbA1c from baseline to the final measurement at 52 weeks [mean (standard deviation)] were −0.000 (0.6225)% in ITG and − 0.006 (0.6449)% in CTG, respectively (<i>P</i> = 0.8766). In the per protocol set, including ITG using the IoT system almost daily and CTG, excluding those using the application almost daily, the difference in HbA1c from baseline to 52 weeks were −0.098 (0.579)% and 0.027 (0.571)%, respectively (<i>P</i> = 0.0201). We observed no significant difference in the adverse event profile between the groups.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The IoT-based approach did not reduce HbA1c in patients with type 2 diabetes. IoT-based intervention using data on the daily glycemic control and HbA1c level may be required to improve glycemic control.</p>\n </section>\n </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11363111/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jdi.14227","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aims

The utilization of long-term effect of internet of things (IoT) on glycemic control is controversial. This trial aimed to examine the effect of an IoT-based approach for type 2 diabetes.

Materials and Methods

This randomized controlled trial enrolled 1,159 adults aged 20–74 years with type 2 diabetes with a HbA1c of 6.0–8.9% (42–74 mmol/mol), who were using a smartphone on a daily basis were randomly assigned to either the IoT-based approach group (ITG) or the control group (CTG). The ITG were supervised to utilize an IoT automated system that demonstrates a summary of lifelogging data (weight, blood pressure, and physical activities) and provides feedback messages that promote behavioral changes in both diet and exercise. The primary end point was a HbA1c change over 52 weeks.

Results

Among the patients, 581 were assigned to the ITG and 578 were in the CTG. The changes in HbA1c from baseline to the final measurement at 52 weeks [mean (standard deviation)] were −0.000 (0.6225)% in ITG and − 0.006 (0.6449)% in CTG, respectively (P = 0.8766). In the per protocol set, including ITG using the IoT system almost daily and CTG, excluding those using the application almost daily, the difference in HbA1c from baseline to 52 weeks were −0.098 (0.579)% and 0.027 (0.571)%, respectively (P = 0.0201). We observed no significant difference in the adverse event profile between the groups.

Conclusions

The IoT-based approach did not reduce HbA1c in patients with type 2 diabetes. IoT-based intervention using data on the daily glycemic control and HbA1c level may be required to improve glycemic control.

Abstract Image

基于物联网的 2 型糖尿病患者血糖控制方法:随机对照试验
目的:利用物联网(IoT)对血糖控制的长期影响还存在争议。本试验旨在研究基于物联网的方法对 2 型糖尿病的影响:这项随机对照试验招募了1159名年龄在20-74岁之间、HbA1c为6.0-8.9%(42-74 mmol/mol)、每天使用智能手机的2型糖尿病患者,将他们随机分配到物联网方法组(ITG)或对照组(CTG)。ITG组在监督下使用物联网自动系统,该系统可显示生活日志数据(体重、血压和体力活动)摘要,并提供反馈信息,促进饮食和运动方面的行为改变。主要终点是 52 周内 HbA1c 的变化:在患者中,581 人被分配到 ITG,578 人被分配到 CTG。从基线到52周最终测量值的HbA1c变化[平均值(标准差)]分别为:ITG为-0.000 (0.6225)%,CTG为- 0.006 (0.6449)%(P = 0.8766)。在按方案组中,包括几乎每天使用物联网系统的 ITG 和不包括几乎每天使用应用程序的 CTG,从基线到 52 周的 HbA1c 差异分别为-0.098 (0.579)% 和 0.027 (0.571)% (P = 0.0201)。我们观察到两组的不良反应情况无明显差异:结论:基于物联网的方法并未降低 2 型糖尿病患者的 HbA1c。可能需要利用日常血糖控制和 HbA1c 水平数据进行基于物联网的干预,以改善血糖控制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Diabetes Investigation
Journal of Diabetes Investigation ENDOCRINOLOGY & METABOLISM-
CiteScore
6.50
自引率
9.40%
发文量
218
审稿时长
6-12 weeks
期刊介绍: Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信